Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Adalimumab (Humira): a brief review for dermatologists.

Scheinfeld N

St Luke's Roosevelt Hospital Center, New York, NY 10025, USA. NSS32@columbia.edu

Adalimumab is a new purely human TNF-alpha monoclonal antibody that has been approved for the treatment of rheumatoid arthritis as monotherapy or in combination with methotrexate. It is administered by subcutaneous injection in a 40-mg dose every other week. The one published Phase II trial of adalimumab for psoriasis has provided very encouraging results for its efficacy. Its most important side effects relate to the development of infection while it is being used. It is a promising medication and research regarding its use continues.

Published 14 March 2005 in J Dermatolog Treat, 15(6): 348-52.
Full-text of this article is available online (may require subscription).

© 2004-2008 Rheumatoid Arthritis Research Today. All Rights Reserved.